We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New Solid State ChIP Technology for Epigenetics

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "New Solid State ChIP Technology for Epigenetics"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Porvair Filtration Group has launched a new web microsite (www.chromatrap.com) dedicated to providing detailed information on its ground breaking solid state Chromatin Immunoprecipitation (ChIP) technology for the Epigenetics market.

The web microsite provides an informative background as to what ChIP technology is about and introduces the new solid state approach pioneered by researchers at Porvair Filtration Group.

Porvair's new Chromatrap® Pro-A technology depends on a porous inert polymer called BioVyon™. Each Chromatrap® spin column contains a BioVyon™ disc with the internal pore structure covalently bonded with Protein A (BioVyon™ Protein A).

Complex mixtures containing the chromatin fragments tagged with the antibody of choice are flowed through the column assisted by centrifugation. The column retains the chromatin of interest whilst unwanted debris is flushed away. Purified chromatin is eluted ready for downstream processing and analysis.

A collaborative case study on the site compares the Chromatrap protocol with results from using a Protein G Magnetic Beads technique. Under optimal conditions, the Chromatrap protocol resulted in a 25.5 fold increase in the percentage DNA pull-down using the exact same sample of MCF7 breast cancer cells, targeting the RNA polymerase II protein bound to the GAPDH target gene.

A further independent case study compares Porvair Chromatrap technology with alternative traditional ChIP methods (Sepharose and Dynabeads). In this study Chromatrap columns were shown to provide a greater level of enrichment of the DNA of interest due to low levels of background binding compared to specific antibody binding.

Also the DNA pull down (percentage input) was significantly higher for the Chromatrap columns than for the other matrices in these assays.